Aurobindo said the approved product has an estimated market size of around USD 73 million for the 12 months ended May 2022. Aurobindo Pharma Ltd on Wednesday said its arm, Eugia Pharma Specialities Ltd, has received a final approval from the US health regulator to manufacture and market Triamcinolone Acetonide injectable suspension indicated for various conditions, including allergies and rheumatoid arthritis. The approval by the US Food & Drug Administration (USFDA) is for Triamcinolone Acetonide injectable suspension for strengths of 200 mg/5 ml and 400 mg/10 ml, multiple dose vials, the company said. The product is being launched this month, it added. It is bioequivalent and therapeutically equivalent to Bristol-Myers Squibb Company's reference listed drug Kenalog-40 injectable suspension, 40 mg/ml, the company said. Citing IQVIA data, Aurobindo said the approved product has an estimated market size of around USD 73 million for the 12 months ended May 2022. Aurobindo said this is the 142nd abbreviated new drug application, including 8 tentative approvals received, out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!